|Bid||50.99 x 2900|
|Ask||51.24 x 1300|
|Day's Range||49.83 - 52.21|
|52 Week Range||41.06 - 96.59|
|Beta (3Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.68|
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Spark Therapeutics Inc. said Thursday it is expanding its research-and-development operations in West Philadelphia in a move expected to create nearly 500 high-paying jobs. The gene therapy company spun out of Children's Hospital of Philadelphia is getting a $2 million Department of Community and Economic Development grant and a $7.5 million grant from the Redevelopment Assistance Capital Program to support the project. Spark's new site will be located on Market Street in Drexel University’s $3 billion Schuylkill Yards development project.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced new data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease. The data from the Investigational New Drug (IND)-enabling studies were presented Saturday, Oct. 6, 2018, in an oral presentation, “Safety and efficacy evaluation of investigational liver gene transfer for secretable GAA in the treatment of Pompe disease,” during the Late Breaking Session at the 23rd International Congress of the World Muscle Society in Argentina.
Swiss drugmaker Roche (ROG.S) is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder. Roche's Hemlibra, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win the U.S. Food and Drug Administration's blessing for use in nearly all patients this week. To hit $5 billion global annual sales that some analysts forecast, Hemlibra must wrest business away from hemophilia giants like Shire (SHP.L), Bayer (BAYGn.DE), Novo Nordisk (NOVOb.CO) and Octapharma, whose "clotting factors" are now standard for people who lack proteins that stop bleeding.
Spark Therapeutics (ONCE) stock closed at $54.85 yesterday, ~76% below its 52-week high of $96.59 on July 9. Spark Therapeutics stock has fallen 12% from $61.61 on August 31. Its 52-week low is $41.06, which it reached on December 11, 2017.
The region attracted $772.79 million in 22 venture capital deals deals during the past 18 months, according to the biotech clusters report.
Caspian was born with a rare, inherited eye disorder called Leber congenital amaurosis, which results in the progressive deterioration of the retina, the tissue at the back of the eye that detects light and color. This month Caspian became among the first patients in the country to receive a new gene-therapy treatment called Luxturna, which his doctors at Oregon Health & Science University believe will improve his vision and prevent further deterioration. The therapy entails inserting a functional gene through harmless, virus-like particles into the retinal cells to compensate for the faulty gene causing his disease.
AG (NOVN.EB) drugs and one Sandoz biosimilar have received a positive European Medicines Agency recommendation, the company and the regulator said in separate statements Friday. Novartis’ Gilenya, a multiple-sclerosis drug, received a positive recommendation for the treatment of children and adolescents with the condition. If approved, the drug would be the first oral disease-modifying therapy for these patients, Novartis said, adding that a full approval would expand the age-range of patients able to use the drug.
A European Medicines Agency panel recommended approval of Spark Therapeutics' gene therapy for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world's costliest treatments outside the United States. The Committee for Medicinal Products for Human Use (CHMP) recommended http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003025.jsp&mid=WC0b01ac058004d5c1 voretigene neparvovec, approved as Luxturna in the United States, for patients suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder that causes vision loss and usually leads to blindness.
Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of LUXTURNA® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. “We are encouraged by today’s decision, which further affirms our pioneering clinical program and brings LUXTURNA one step closer to patients with inherited retinal disease (IRD) caused by mutations in both copies of the RPE65 gene in the European Union,” said Katherine A. High, M.D., president and head of research & development at Spark Therapeutics.
Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.
Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.
Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).
Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system. In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles. Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock.
Today, Exelixis announced that the NCCN (National Comprehensive Cancer Network) had updated its clinical practice guidelines, in which it recommended Cabometyx tablets for the treatment of individuals with advanced renal cell carcinoma irrespective of the patient’s risk status. The NCCN’s clinical practice guidelines for kidney cancer now recommend Cabometyx as the only preferred TKI (tyrosine kinase inhibitor) therapy in treatment-naïve patients who are in the poor to intermediate risk group.
Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.
NEW YORK, Aug. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta ...
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.
Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.